Despite growing interest, the development of complement-targeted drugs has been slow, with two related anti-C5 antibodies (eculizumab, ravulizumab) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other indications long remaining the only clinical options2. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.